

Monoclonal Antibodies To Delay Coagulation Factor XIII Activation

Tech ID: 34636 / UC Case 2024-222-0

INVENTION NOVELTY

VALUE PROPOSITION

TECHNOLOGY DESCRIPTION

UCSF researchers have developed antibodies that will delay coagulation factor XIII (FXIII) activation during coagulation. In vitro, the researchers have shown a delay in FXIII activation and reduction in clot size.

APPLICATION

LOOKING FOR PARTNERS

STAGE OF DEVELOPMENT

RELATED MATERIALS

DATA AVAILABILITY

CONTACT

Kristin A. Agopian
kristin.agopian@ucsf.edu
 tel: 415-340-2619.



OTHER INFORMATION

KEYWORDS

Coagulation, factor XIII (FXIII), fibrinogen, antibodies, clot, UCSF innovation

CATEGORIZED AS

- ▶ **Biotechnology**
- ▶ Health
- ▶ **Materials & Chemicals**
- ▶ Biological
- ▶ **Research Tools**
- ▶ Antibodies

RELATED CASES

2024-222-0

ADDRESS

UCSF

Innovation Ventures

CONTACT

Tel:

innovation@ucsf.edu

CONNECT

Follow   Connect

600 16th St, Genentech Hall, S-272,
San Francisco, CA 94158

<https://innovation.ucsf.edu>

Fax:

© 2026, The Regents of the University of
California

[Terms of use](#) [Privacy Notice](#)